6533b873fe1ef96bd12d5742

RESEARCH PRODUCT

Microsatellite Instability in Colorectal Cancer: Time to Stop Hiding!

Ada ColluraCarmen GarridoAnaïs LagrangeAlex DuvalKevin Berthenet

subject

Pathologymedicine.medical_specialtyChemotherapyColorectal cancermedicine.medical_treatmentMicrosatellite instabilityDiseaseBiologymedicine.diseasedigestive system diseasesTherapeutic approachOncologyChromosome instabilityCancer researchmedicineMicrosatelliteAnimalsHumansIn patientMicrosatellite InstabilityHSP110 Heat-Shock ProteinsColorectal NeoplasmsneoplasmsEditorial Comments

description

Colorectal cancer (CRC) is the second cause of cancer-related death worldwide. Surgery constitutes the primary therapy for these tumors, together with chemotherapy that is usually recommended in patients with metastatic primary CRC. Although molecularly distinct entities arising from different physiopathogenic mechanisms - microsatellite (MSI) and chromosomal instability (also called microsatellite stable, MSS) - have been characterized in CRC, there is still no specific therapeutic approach that takes into account disease’s molecular heterogeneity [1]. MSI is observed in 1015% of sporadic CRCs. MSI CRCs displayed particular morphologic features, with greater predilection for the right colon, mucinous histology, low metastatic power, poorer differentiation and higher numbers of tumorinfiltrating lymphocytes. They have been consistently reported to show an improved prognosis and a different response to chemotherapeutic agents. In a recent article in Nature Medicine, we have reported the specific mutation of the molecular chaperone HSP110 in MSI CRCs and how the presence of this mutant may constitute a first step towards the understanding of their particular clinical characteristics [2].

yearjournalcountryeditionlanguage
2011-11-12Oncotarget
http://europepmc.org/articles/PMC3259994